⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for stage iv uterine corpus cancer ajcc v8

Every month we try and update this database with for stage iv uterine corpus cancer ajcc v8 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid TumorsNCT05039801
Advanced Endome...
Advanced Head a...
Advanced Malign...
Advanced Melano...
Advanced Ovaria...
Chondrosarcoma
Clinical Stage ...
Clinical Stage ...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Recurrent Ovari...
Refractory Endo...
Refractory Head...
Refractory Mela...
Refractory Ovar...
Refractory Ovar...
Stage III Ovari...
Stage III Uteri...
Stage IIIA Ovar...
Stage IIIA Uter...
Stage IIIA1 Ova...
Stage IIIA2 Ova...
Stage IIIB Ovar...
Stage IIIB Uter...
Stage IIIC Ovar...
Stage IIIC Uter...
Stage IIIC1 Ute...
Stage IIIC2 Ute...
Stage IV Ovaria...
Stage IV Uterin...
Stage IVA Ovari...
Stage IVA Uteri...
Stage IVB Ovari...
Stage IVB Uteri...
Bevacizumab
Glutaminase-1 I...
Paclitaxel
Capivasertib
18 Years - M.D. Anderson Cancer Center
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH TrialNCT04704661
Advanced Breast...
Advanced Colon ...
Advanced Colore...
Advanced Endome...
Advanced Gastri...
Advanced Gastro...
Advanced Malign...
Advanced Saliva...
Anatomic Stage ...
Anatomic Stage ...
Anatomic Stage ...
Anatomic Stage ...
Anatomic Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
HER2-Positive B...
Malignant Hepat...
Metastatic Brea...
Metastatic Gast...
Metastatic Mali...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Prognostic Stag...
Prognostic Stag...
Prognostic Stag...
Prognostic Stag...
Prognostic Stag...
Stage III Colon...
Stage III Color...
Stage III Major...
Stage III Uteri...
Stage IIIA Colo...
Stage IIIA Colo...
Stage IIIA Uter...
Stage IIIB Colo...
Stage IIIB Colo...
Stage IIIB Uter...
Stage IIIC Colo...
Stage IIIC Colo...
Stage IIIC Uter...
Stage IIIC1 Ute...
Stage IIIC2 Ute...
Stage IV Colon ...
Stage IV Colore...
Stage IV Major ...
Stage IV Uterin...
Stage IVA Colon...
Stage IVA Color...
Stage IVA Major...
Stage IVA Uteri...
Stage IVB Colon...
Stage IVB Color...
Stage IVB Major...
Stage IVB Uteri...
Stage IVC Colon...
Stage IVC Color...
Stage IVC Major...
Unresectable Co...
Unresectable Ga...
Unresectable Ma...
Ceralasertib
Trastuzumab Der...
18 Years - National Cancer Institute (NCI)
Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial CancerNCT03367741
Advanced Endome...
Metastatic Endo...
Recurrent Endom...
Stage III Uteri...
Stage IV Uterin...
Biopsy
Biospecimen Col...
Cabozantinib S-...
Computed Tomogr...
Magnetic Resona...
Nivolumab
18 Years - National Cancer Institute (NCI)
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or ThoraxNCT05092373
Advanced Breast...
Advanced Endome...
Advanced Fallop...
Advanced Hepato...
Advanced Malign...
Advanced Malign...
Advanced Malign...
Advanced Ovaria...
Advanced Primar...
Advanced Renal ...
Anatomic Stage ...
Anatomic Stage ...
Anatomic Stage ...
Anatomic Stage ...
Anatomic Stage ...
Malignant Abdom...
Malignant Solid...
Metastatic Brea...
Metastatic Endo...
Metastatic Fall...
Metastatic Hepa...
Metastatic Mali...
Metastatic Mali...
Metastatic Mali...
Metastatic Ovar...
Metastatic Prim...
Metastatic Rena...
Prognostic Stag...
Prognostic Stag...
Prognostic Stag...
Prognostic Stag...
Prognostic Stag...
Stage III Fallo...
Stage III Hepat...
Stage III Ovari...
Stage III Prima...
Stage III Renal...
Stage III Uteri...
Stage IIIA Fall...
Stage IIIA Hepa...
Stage IIIA Ovar...
Stage IIIA Prim...
Stage IIIA Uter...
Stage IIIA1 Fal...
Stage IIIA1 Ova...
Stage IIIA2 Fal...
Stage IIIA2 Ova...
Stage IIIB Fall...
Stage IIIB Hepa...
Stage IIIB Ovar...
Stage IIIB Prim...
Stage IIIB Uter...
Stage IIIC Fall...
Stage IIIC Ovar...
Stage IIIC Prim...
Stage IIIC Uter...
Stage IIIC1 Ute...
Stage IIIC2 Ute...
Stage IV Fallop...
Stage IV Hepato...
Stage IV Ovaria...
Stage IV Primar...
Stage IV Renal ...
Stage IV Uterin...
Stage IVA Fallo...
Stage IVA Hepat...
Stage IVA Ovari...
Stage IVA Prima...
Stage IVA Uteri...
Stage IVB Fallo...
Stage IVB Hepat...
Stage IVB Ovari...
Stage IVB Prima...
Stage IVB Uteri...
Atezolizumab
Cabozantinib S-...
Nab-paclitaxel
Tumor Treating ...
18 Years - M.D. Anderson Cancer Center
A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial CarcinomaNCT03008408
Recurrent Endom...
Recurrent Endom...
Refractory Endo...
Refractory Endo...
Stage III Uteri...
Stage IIIA Uter...
Stage IIIB Uter...
Stage IIIC Uter...
Stage IIIC1 Ute...
Stage IIIC2 Ute...
Stage IV Uterin...
Stage IVA Uteri...
Stage IVB Uteri...
Everolimus
Letrozole
Ribociclib
18 Years - M.D. Anderson Cancer Center
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial CancersNCT05691504
Advanced Endome...
Metastatic Endo...
Metastatic Fall...
Metastatic Plat...
Metastatic Prim...
Recurrent Endom...
Recurrent Fallo...
Recurrent Plati...
Recurrent Prima...
Stage III Uteri...
Stage IV Uterin...
Biopsy
Biospecimen Col...
Cobimetinib
Computed Tomogr...
Echocardiograph...
Magnetic Resona...
Multigated Acqu...
Pelcitoclax
18 Years - National Cancer Institute (NCI)
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric CancerNCT04329494
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Malignant Uteri...
Metastatic Appe...
Metastatic Colo...
Metastatic Gast...
Metastatic Mali...
Metastatic Mali...
Metastatic Ovar...
Pathologic Stag...
Peritoneal Carc...
Postneoadjuvant...
Stage IV Append...
Stage IV Colore...
Stage IV Ovaria...
Stage IV Uterin...
Stage IVA Appen...
Stage IVA Color...
Stage IVA Ovari...
Stage IVA Uteri...
Stage IVB Appen...
Stage IVB Color...
Stage IVB Ovari...
Stage IVB Uteri...
Stage IVC Appen...
Stage IVC Color...
Biopsy
Cisplatin
Doxorubicin
Fluorouracil
Intraperitoneal...
Irinotecan
Leucovorin
Mitomycin
Oxaliplatin
Quality-of-Life...
Questionnaire A...
18 Years - City of Hope Medical Center
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic CancersNCT03968406
Malignant Femal...
Recurrent Cervi...
Recurrent Endom...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Recurrent Vagin...
Stage IV Cervic...
Stage IV Fallop...
Stage IV Ovaria...
Stage IV Primar...
Stage IV Uterin...
Stage IV Vagina...
Stage IVA Cervi...
Stage IVA Fallo...
Stage IVA Ovari...
Stage IVA Prima...
Stage IVA Uteri...
Stage IVA Vagin...
Stage IVB Cervi...
Stage IVB Fallo...
Stage IVB Ovari...
Stage IVB Prima...
Stage IVB Uteri...
Stage IVB Vagin...
Quality-of-Life...
Radiation Thera...
Talazoparib
18 Years - M.D. Anderson Cancer Center
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid TumorsNCT05039801
Advanced Endome...
Advanced Head a...
Advanced Malign...
Advanced Melano...
Advanced Ovaria...
Chondrosarcoma
Clinical Stage ...
Clinical Stage ...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Recurrent Ovari...
Refractory Endo...
Refractory Head...
Refractory Mela...
Refractory Ovar...
Refractory Ovar...
Stage III Ovari...
Stage III Uteri...
Stage IIIA Ovar...
Stage IIIA Uter...
Stage IIIA1 Ova...
Stage IIIA2 Ova...
Stage IIIB Ovar...
Stage IIIB Uter...
Stage IIIC Ovar...
Stage IIIC Uter...
Stage IIIC1 Ute...
Stage IIIC2 Ute...
Stage IV Ovaria...
Stage IV Uterin...
Stage IVA Ovari...
Stage IVA Uteri...
Stage IVB Ovari...
Stage IVB Uteri...
Bevacizumab
Glutaminase-1 I...
Paclitaxel
Capivasertib
18 Years - M.D. Anderson Cancer Center
e-Health Intervention (Day-by-Day) for the Management of Fear of Progression in Women With Stage III or IV Gynecologic Cancer: A Pilot StudyNCT05786456
Malignant Femal...
Stage III Cervi...
Stage III Ovari...
Stage III Uteri...
Stage III Vagin...
Stage III Vulva...
Stage IV Cervic...
Stage IV Ovaria...
Stage IV Uterin...
Stage IV Vagina...
Stage IV Vulvar...
Discussion
Informational I...
Media Intervent...
Questionnaire A...
Telephone-Based...
18 Years - City of Hope Medical Center
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial CancerNCT03914612
Endometrial Cle...
Endometrial Ded...
Endometrial End...
Endometrial Mix...
Endometrial Ser...
Endometrial Und...
Recurrent Endom...
Recurrent Endom...
Recurrent Endom...
Recurrent Endom...
Recurrent Endom...
Recurrent Endom...
Recurrent Endom...
Recurrent Endom...
Stage III Uteri...
Stage IV Uterin...
Carboplatin
Computed Tomogr...
Paclitaxel
Pembrolizumab
Placebo Adminis...
Quality-of-Life...
Questionnaire A...
18 Years - National Cancer Institute (NCI)
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib AloneNCT03660826
Endometrial Ade...
Endometrial Mix...
Endometrial Ser...
Endometrial Und...
Endometrioid Ad...
Stage IV Uterin...
Biospecimen Col...
Bone Marrow Asp...
Bone Marrow Bio...
Capivasertib
Cediranib
Cediranib Malea...
Computed Tomogr...
Durvalumab
Echocardiograph...
Multigated Acqu...
Olaparib
18 Years - National Cancer Institute (NCI)
Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial CancersNCT05538897
FIGO Grade 1 En...
FIGO Grade 2 En...
Metastatic Endo...
Recurrent Endom...
Stage IV Uterin...
Biospecimen Col...
Computed Tomogr...
Ipatasertib
Magnetic Resona...
Megestrol Aceta...
18 Years - National Cancer Institute (NCI)
Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported OutcomesNCT04501913
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Hepatobiliary N...
Malignant Diges...
Malignant Femal...
Malignant Genit...
Malignant Neopl...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Stage 0 Colorec...
Stage 0a Bladde...
Stage 0is Bladd...
Stage I Bladder...
Stage I Cervica...
Stage I Colorec...
Stage I Ovarian...
Stage I Prostat...
Stage I Renal C...
Stage I Uterine...
Stage IA Cervic...
Stage IA Ovaria...
Stage IA Uterin...
Stage IA1 Cervi...
Stage IA2 Cervi...
Stage IB Cervic...
Stage IB Ovaria...
Stage IB Uterin...
Stage IB1 Cervi...
Stage IB2 Cervi...
Stage IC Ovaria...
Stage II Bladde...
Stage II Cervic...
Stage II Colore...
Stage II Ovaria...
Stage II Prosta...
Stage II Renal ...
Stage II Uterin...
Stage IIA Cervi...
Stage IIA Color...
Stage IIA Ovari...
Stage IIA Prost...
Stage IIA1 Cerv...
Stage IIA2 Cerv...
Stage IIB Cervi...
Stage IIB Color...
Stage IIB Ovari...
Stage IIB Prost...
Stage IIC Color...
Stage IIC Prost...
Stage III Bladd...
Stage III Cervi...
Stage III Color...
Stage III Ovari...
Stage III Prost...
Stage III Renal...
Stage III Uteri...
Stage IIIA Blad...
Stage IIIA Cerv...
Stage IIIA Colo...
Stage IIIA Ovar...
Stage IIIA Pros...
Stage IIIA Uter...
Stage IIIA1 Ova...
Stage IIIA2 Ova...
Stage IIIB Blad...
Stage IIIB Cerv...
Stage IIIB Colo...
Stage IIIB Ovar...
Stage IIIB Pros...
Stage IIIB Uter...
Stage IIIC Colo...
Stage IIIC Ovar...
Stage IIIC Pros...
Stage IIIC Uter...
Stage IIIC1 Ute...
Stage IIIC2 Ute...
Stage IV Bladde...
Stage IV Cervic...
Stage IV Colore...
Stage IV Ovaria...
Stage IV Prosta...
Stage IV Renal ...
Stage IV Uterin...
Stage IVA Bladd...
Stage IVA Cervi...
Stage IVA Color...
Stage IVA Ovari...
Stage IVA Prost...
Stage IVA Uteri...
Stage IVB Bladd...
Stage IVB Cervi...
Stage IVB Color...
Stage IVB Ovari...
Stage IVB Prost...
Stage IVB Uteri...
Stage IVC Color...
Patient Monitor...
Questionnaire A...
18 Years - City of Hope Medical Center
Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial CancerNCT03367741
Advanced Endome...
Metastatic Endo...
Recurrent Endom...
Stage III Uteri...
Stage IV Uterin...
Biopsy
Biospecimen Col...
Cabozantinib S-...
Computed Tomogr...
Magnetic Resona...
Nivolumab
18 Years - National Cancer Institute (NCI)
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial CancersNCT05691504
Advanced Endome...
Metastatic Endo...
Metastatic Fall...
Metastatic Plat...
Metastatic Prim...
Recurrent Endom...
Recurrent Fallo...
Recurrent Plati...
Recurrent Prima...
Stage III Uteri...
Stage IV Uterin...
Biopsy
Biospecimen Col...
Cobimetinib
Computed Tomogr...
Echocardiograph...
Magnetic Resona...
Multigated Acqu...
Pelcitoclax
18 Years - National Cancer Institute (NCI)
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib AloneNCT03660826
Endometrial Ade...
Endometrial Mix...
Endometrial Ser...
Endometrial Und...
Endometrioid Ad...
Stage IV Uterin...
Biospecimen Col...
Bone Marrow Asp...
Bone Marrow Bio...
Capivasertib
Cediranib
Cediranib Malea...
Computed Tomogr...
Durvalumab
Echocardiograph...
Multigated Acqu...
Olaparib
18 Years - National Cancer Institute (NCI)
Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic CancerNCT04498520
Anatomic Stage ...
Anatomic Stage ...
Anatomic Stage ...
Anatomic Stage ...
Anatomic Stage ...
Hormone Recepto...
Locally Advance...
Metastatic Brea...
Metastatic Endo...
Metastatic Fall...
Metastatic HER2...
Metastatic Mali...
Metastatic Ovar...
Metastatic Prim...
Prognostic Stag...
Prognostic Stag...
Prognostic Stag...
Prognostic Stag...
Prognostic Stag...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Refractory Brea...
Stage IV Fallop...
Stage IV Ovaria...
Stage IV Primar...
Stage IV Uterin...
Stage IVA Fallo...
Stage IVA Ovari...
Stage IVA Prima...
Stage IVA Uteri...
Stage IVB Fallo...
Stage IVB Ovari...
Stage IVB Prima...
Stage IVB Uteri...
Abexinostat Tos...
Fulvestrant
Palbociclib
18 Years - University of California, San Francisco
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid TumorsNCT05039801
Advanced Endome...
Advanced Head a...
Advanced Malign...
Advanced Melano...
Advanced Ovaria...
Chondrosarcoma
Clinical Stage ...
Clinical Stage ...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Recurrent Ovari...
Refractory Endo...
Refractory Head...
Refractory Mela...
Refractory Ovar...
Refractory Ovar...
Stage III Ovari...
Stage III Uteri...
Stage IIIA Ovar...
Stage IIIA Uter...
Stage IIIA1 Ova...
Stage IIIA2 Ova...
Stage IIIB Ovar...
Stage IIIB Uter...
Stage IIIC Ovar...
Stage IIIC Uter...
Stage IIIC1 Ute...
Stage IIIC2 Ute...
Stage IV Ovaria...
Stage IV Uterin...
Stage IVA Ovari...
Stage IVA Uteri...
Stage IVB Ovari...
Stage IVB Uteri...
Bevacizumab
Glutaminase-1 I...
Paclitaxel
Capivasertib
18 Years - M.D. Anderson Cancer Center
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial CancersNCT05691504
Advanced Endome...
Metastatic Endo...
Metastatic Fall...
Metastatic Plat...
Metastatic Prim...
Recurrent Endom...
Recurrent Fallo...
Recurrent Plati...
Recurrent Prima...
Stage III Uteri...
Stage IV Uterin...
Biopsy
Biospecimen Col...
Cobimetinib
Computed Tomogr...
Echocardiograph...
Magnetic Resona...
Multigated Acqu...
Pelcitoclax
18 Years - National Cancer Institute (NCI)
Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic CancerNCT04498520
Anatomic Stage ...
Anatomic Stage ...
Anatomic Stage ...
Anatomic Stage ...
Anatomic Stage ...
Hormone Recepto...
Locally Advance...
Metastatic Brea...
Metastatic Endo...
Metastatic Fall...
Metastatic HER2...
Metastatic Mali...
Metastatic Ovar...
Metastatic Prim...
Prognostic Stag...
Prognostic Stag...
Prognostic Stag...
Prognostic Stag...
Prognostic Stag...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Refractory Brea...
Stage IV Fallop...
Stage IV Ovaria...
Stage IV Primar...
Stage IV Uterin...
Stage IVA Fallo...
Stage IVA Ovari...
Stage IVA Prima...
Stage IVA Uteri...
Stage IVB Fallo...
Stage IVB Ovari...
Stage IVB Prima...
Stage IVB Uteri...
Abexinostat Tos...
Fulvestrant
Palbociclib
18 Years - University of California, San Francisco
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: